Several studies have demonstrated that high levels of CXCL13+ cells or CXCL13 expression in the TME could be used as a prognostic biomarker for ICI-treated bladder cancer and ovarian cancer patients and is associated with prolonged survival and objective response [21,22,23]. This evidence concerns the gene CXCL13 and urinary bladder carcinoma.